TY - JOUR
T1 - Impact of serum antibodies to HPV serotypes 6, 11, 16, and 18 to risks of subsequent genital HPV infections in men
T2 - The HIM study
AU - Pamnani, Shitaldas J.
AU - Sudenga, Staci L.
AU - Viscidi, Raphael
AU - Rollison, Dana E.
AU - Torres, B. Nelson
AU - Ingles, Donna J.
AU - Abrahamsen, Martha
AU - Villa, Luisa L.
AU - Lazcano-Ponce, Eduardo
AU - Salmeron, Jorge
AU - Quiterio, Manuel
AU - Huang, Yangxin
AU - Borenstein, Amy
AU - Giuliano, Anna R.
N1 - Funding Information:
S.L. Sudenga reports receiving a commercial research grant from Merck and Co. L.L. Villa has received speakers bureau honoraria from and is a consultant/advisory board member for Merck, Sharp and Dohme. A.R. Giuliano is a consultant/advisory board member for Merck. No potential conflicts of interest were disclosed by the other authors. The authors thank the HIM Study teams in the United States (Hui-Yi Lin, Jane Messina, Christine Pierce Campbell, Bradley Sirak, Christine Gage, Kim Isaacs, Kayoko Kennedy, Andrea Bobanic, Shams Rahman, Matthew Schabath, Alan Nyitray, and Julie Rathwell), Brazil (Maria Luiza Baggio, Roberto Carvalho da Silva, Lenice Galan, Ricardo Cintra, Filomena Cernicchiaro, Graça Ribeiro, Rosária Otero, Roberta Bocalon, Juliana Antunes, Fernanda Silva, Rossana Terreri, and the CRT-DST/AIDS nursing team), and Mexico (Aurelio Cruz Valdez, René de Jesús Alvear Vásquez, Oscar Rojas Juárez, Rossana del Carmen González Sosa, Rosangel Ríos Vences, Martha Huerta Segura, Alicia Rodríguez Galván, Paula Román Rodríguez, Ana Laura Landa Vélez, Griselda Díaz García, Verónica Chávez Abarca, Gisela Flores Quevedo, María del Pilar Hernández Nevárez, Guillermina Sánchez Martínez, Adriana Ortiz Rojas, and Carlos Omar Barrera Flores). A.R. Giuliano, B.N Torres, D.J. Ingles, M. Abrahamsen, L.L. Villa, E. Lazcano-Ponce, J. Salmeron, and M. Quiterio received financial support from the NCI, NIH CA R01CA098803 (principal investigator: A.R. Giuliano). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher Copyright:
©2016 AACR.
PY - 2016/10/15
Y1 - 2016/10/15
N2 - Naturally induced serum antibodies against human papillomavirus (HPV) may affect risks of subsequent incident genital infections by HPV 6, 11, 16, or 18 in men. In this study, we examined the hypothesis by following 4,123 healthy men every 6 months (median follow-up time, 4.1 years). HPV antibodies were measured at baseline using a virus-like particle-based ELISA assay. Genital HPV genotypes were detected using Roche Linear Array. Incidence proportions and 6-month persistence proportions were calculated at 6-month intervals. Kaplan-Meier curves and Cox models were used to assess genotype-specific cumulative incidence and HRs, respectively. HPV 6, 11, 16, and 18 seroprevalence was 8.1%, 13.9%, 12.7%, and 10.8%, respectively. Significantly higher rates of incident infections were observed for HPV 16 among baseline-seropositive men [adjusted HR, 1.37; 95% confidence interval (CI), 1.01-1.86], with similar but nonsignificant HRs for 6-month persistent infections. Risk of persistent HPV 18 infection was significantly lower among seropositive men in the unadjusted model (HR, 0.22; 95% CI, 0.06-0.91), but not in the adjusted model (HR, 0.19; 95% CI, 0.03-1.37). Incident and 6-month persistent infections for HPV 6 and 11 did not differ by baseline serostatus. Baseline serostatus among men was not associated with a reduction in subsequent incident genital HPV 6, 11, and 16 infections. However, protection against persistent HPV18 infections was observed in unadjusted models. Our research suggests a need of further studies to examine the potentially protective effects of naturally induced HPV18 antibodies in men.
AB - Naturally induced serum antibodies against human papillomavirus (HPV) may affect risks of subsequent incident genital infections by HPV 6, 11, 16, or 18 in men. In this study, we examined the hypothesis by following 4,123 healthy men every 6 months (median follow-up time, 4.1 years). HPV antibodies were measured at baseline using a virus-like particle-based ELISA assay. Genital HPV genotypes were detected using Roche Linear Array. Incidence proportions and 6-month persistence proportions were calculated at 6-month intervals. Kaplan-Meier curves and Cox models were used to assess genotype-specific cumulative incidence and HRs, respectively. HPV 6, 11, 16, and 18 seroprevalence was 8.1%, 13.9%, 12.7%, and 10.8%, respectively. Significantly higher rates of incident infections were observed for HPV 16 among baseline-seropositive men [adjusted HR, 1.37; 95% confidence interval (CI), 1.01-1.86], with similar but nonsignificant HRs for 6-month persistent infections. Risk of persistent HPV 18 infection was significantly lower among seropositive men in the unadjusted model (HR, 0.22; 95% CI, 0.06-0.91), but not in the adjusted model (HR, 0.19; 95% CI, 0.03-1.37). Incident and 6-month persistent infections for HPV 6 and 11 did not differ by baseline serostatus. Baseline serostatus among men was not associated with a reduction in subsequent incident genital HPV 6, 11, and 16 infections. However, protection against persistent HPV18 infections was observed in unadjusted models. Our research suggests a need of further studies to examine the potentially protective effects of naturally induced HPV18 antibodies in men.
UR - http://www.scopus.com/inward/record.url?scp=84991710672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991710672&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-16-0224
DO - 10.1158/0008-5472.CAN-16-0224
M3 - Article
C2 - 27535333
AN - SCOPUS:84991710672
SN - 0008-5472
VL - 76
SP - 6066
EP - 6075
JO - Cancer Research
JF - Cancer Research
IS - 20
ER -